MahaH. A.HussainMDFACP, FASCO

Clinical Trials

• SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer Start of enrollment: 1995 May 01

  Completed

  Phase 3

• Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Start of enrollment: 1997 Mar 01

  Completed

  Phase 3

• Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy Start of enrollment: 1998 Oct 01

  Completed

  Phase 2

• Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer Start of enrollment: 2000 Mar 01

  Completed

  Phase 2

• S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Start of enrollment: 2000 Nov 01

  Completed

  Phase 2

• BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 2001 Jun 01

  Completed

  Phase 2

• Cilengitide in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2005 Jan 01

  Completed

  Phase 2

• Cilengitide in Treating Patients With Prostate Cancer Start of enrollment: 2005 Jan 01

  Completed

  Phase 2

• S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Start of enrollment: 2006 Aug 01

  Completed

  Phase 3

• Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer Start of enrollment: 2000 Sep 01

  Completed

  Phase 2

• Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer Start of enrollment: 2003 Mar 01

  Completed

  Phase 2

• Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma Start of enrollment: 2006 May 01

  Terminated

  Phase 2

• Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer Start of enrollment: 2008 Mar 01

  Completed

  Phase 2

• A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer Start of enrollment: 2005 Feb 01

  Terminated

  Phase 2

• Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer Start of enrollment: 2009 Oct 01

  Terminated

  Phase 2

• Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer Start of enrollment: 2011 Feb 01

  Unknown status

  Phase 2

• Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30

  Completed

  Phase 2

• A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer Start of enrollment: 2014 Jun 01

  Completed

  Phase 2

• Early Assessment of Treatment Response Using Functional Diffusion Mapping Start of enrollment: 2007 May 01

  Completed

  Not Applicable

• Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects Start of enrollment: 2017 Jan 12

  Active, not recruiting

  Phase 2

• Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma Start of enrollment: 2019 Nov 18

  Active, not recruiting

  Phase 1, Phase 2

• sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2019 Sep 20

  Active, not recruiting

  Phase 2

• Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer Start of enrollment: 2016 May 03

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• Join now to see all